Save Article

Acambis Will Speed Development
Of Smallpox Vaccine, After Attacks

LONDON -- Following terrorist attacks in the U.S. last week, Acambis PLC is speeding up the development of a vaccine to combat the effects of biological warfare.

The biotechnology company last September signed a contract with the U.S. government to supply 40 million doses of a vaccine against smallpox, a disease thought likely to be among those disseminated in any potential biological warfare.